Technology Platform for Enhanced Vascular Health
Our Goal is to revolutionize vascular implants with either anti-thrombotic or thrombotic surface modification technologies
The Challenge
30% of patients with vascular implants experience thrombosis, which can lead to severe health issues, including heart attacks and strokes
Impact on Patients
5-10% risk of major bleeding events within the first year of DAPT Patients undergoing Dual Anti-Platelet Therapy (DAPT) face a dual risk of both thrombosis and bleeding
Economic Burden:
Average cost of treating a major bleeding event: $50,000 Average cost of managing a thrombotic event: $100,000 Total annual cost of DAPT to healthcare system in US: ~$3.1Billion
Market Need:
Over 10 million vascular implant procedures annually worldwide
Our Focus, commitment and acheivement
R&D Focus
Innovative Technology:
Dedicated to developing new anti-thrombosis technology utilizing electric potential.
Aims to address limitations of existing market solutions with a novel approach.
Research Commitment:
Significant resources and expertise allocated to advancing this cutting-edge solution.
Bench Test Achievements
Bench tests reveal promising results: Surpassing performance of market-leading technologies.